Interplay between estrogen receptor and AKT in Estradiol-induced alternative splicing

dc.contributor.authorBhat-Nakshatri, Poornima
dc.contributor.authorSong, Eun-Kyung
dc.contributor.authorCollins, Nikail R
dc.contributor.authorUversky, Vladimir N
dc.contributor.authorDunker, A Keith
dc.contributor.authorO’Malley, Bert W
dc.contributor.authorGeistlinger, Tim R
dc.contributor.authorCarroll, Jason S
dc.contributor.authorBrown, Myles
dc.contributor.authorNakshatri, Harikrishna
dc.date.accessioned2019-03-28T21:43:44Z
dc.date.available2019-03-28T21:43:44Z
dc.date.issued2013-06-11
dc.description.abstractBackground Alternative splicing is critical for generating complex proteomes in response to extracellular signals. Nuclear receptors including estrogen receptor alpha (ERα) and their ligands promote alternative splicing. The endogenous targets of ERα:estradiol (E2)-mediated alternative splicing and the influence of extracellular kinases that phosphorylate ERα on E2-induced splicing are unknown. Methods MCF-7 and its anti-estrogen derivatives were used for the majority of the assays. CD44 mini gene was used to measure the effect of E2 and AKT on alternative splicing. ExonHit array analysis was performed to identify E2 and AKT-regulated endogenous alternatively spliced apoptosis-related genes. Quantitative reverse transcription polymerase chain reaction was performed to verify alternative splicing. ERα binding to alternatively spliced genes was verified by chromatin immunoprecipitation assay. Bromodeoxyuridine incorporation-ELISA and Annexin V labeling assays were done to measure cell proliferation and apoptosis, respectively. Results We identified the targets of E2-induced alternative splicing and deconstructed some of the mechanisms surrounding E2-induced splicing by combining splice array with ERα cistrome and gene expression array. E2-induced alternatively spliced genes fall into at least two subgroups: coupled to E2-regulated transcription and ERα binding to the gene without an effect on rate of transcription. Further, AKT, which phosphorylates both ERα and splicing factors, influenced ERα:E2 dependent splicing in a gene-specific manner. Genes that are alternatively spliced include FAS/CD95, FGFR2, and AXIN-1. E2 increased the expression of FGFR2 C1 isoform but reduced C3 isoform at mRNA level. E2-induced alternative splicing of FAS and FGFR2 in MCF-7 cells correlated with resistance to FAS activation-induced apoptosis and response to keratinocyte growth factor (KGF), respectively. Resistance of MCF-7 breast cancer cells to the anti-estrogen tamoxifen was associated with ERα-dependent overexpression of FGFR2, whereas resistance to fulvestrant was associated with ERα-dependent isoform switching, which correlated with altered response to KGF. Conclusion E2 may partly alter cellular proteome through alternative splicing uncoupled to its effects on transcription initiation and aberration in E2-induced alternative splicing events may influence response to anti-estrogens.en_US
dc.identifier.citationBhat-Nakshatri, P., Song, E.-K., Collins, N. R., Uversky, V. N., Dunker, A. K., O’Malley, B. W., … Nakshatri, H. (2013). Interplay between estrogen receptor and AKT in Estradiol-induced alternative splicing. BMC Medical Genomics, 6, 21. https://doi.org/10.1186/1755-8794-6-21en_US
dc.identifier.doi10.1186/1755-8794-6-21
dc.identifier.issn1755-8794
dc.identifier.urihttps://hdl.handle.net/1805/18724
dc.language.isoen_USen_US
dc.publisherBMCen_US
dc.rightsAttribution 3.0 United States
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/
dc.subjectestrogenen_US
dc.subjectextracellular signalsen_US
dc.subjectsplicingen_US
dc.titleInterplay between estrogen receptor and AKT in Estradiol-induced alternative splicingen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
1755-8794-6-21.pdf
Size:
2.59 MB
Format:
Adobe Portable Document Format
Description:
Article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: